A new paper in the Annals of Oncology has addressed the critical question regarding what might be “the best” way we currently have to start treatment for a man newly diagnosed with metastatic, hormone-sensitive prostate cancer (mHSPC). Vale et al. carried out a meta-analysis of data from a total of 10 completed trials which had […]
↧